Selank Dosage Chart: 1mg SubQ, 2-3x/Week Protocol

Selank (TP-7) is a synthetic heptapeptide derived from the immunomodulatory peptide tuftsin, approved in Russia as a nasal spray for anxiety and neurasthenia. It has genuine human clinical trial data — a 2008 Russian clinical trial (Zozulya et al.) documented anxiolytic efficacy comparable to benzodiazepines without sedation, tolerance, or dependence.

Research-context information only. Selank is a research peptide. Protocols, doses, and reactions reported below come from published research and self-reported community sources. This article reports what has been documented, not what should be done. Consult a licensed physician for personal medical decisions.

Selank is not FDA-approved. It has clinical approval in Russia only. This is not medical advice. For a deeper look at how Selank works, see our Selank benefits guide.

Quick Reference: Standard Protocol

Cycling Details

The standard cycle is 1 mg subcutaneous in the morning, 2-3 days per week, for 8 weeks on / 8 weeks off.

Weeks 1-2 (Assessment): Documented protocols begin at 1 mg, 2 days per week, to gauge anxiolytic response. Some users report effects within the first dose; others require several days.

Weeks 3-8 (Maintenance): Continue at 1 mg, 2-3 days per week based on response.

Off-cycle: Selank doesn't show tolerance in clinical studies, but cycling is a conservative approach to maintain receptor sensitivity. Community sources describe avoiding late evening dosing — some users report mild stimulating effects.

Routes of Administration

Intranasal spray is the original and most-studied route — Selank was developed as a nasal formulation. Clinical protocols used 250-300 mcg intranasally, 3 times daily for 14 days.

Subcutaneous injection is the community alternative, offering more consistent absorption. Documented community protocols describe the abdomen or love handles as standard injection sites, using 29–31 gauge insulin syringes.

Reconstitution Quick Reference

Math: 30 mg / 3 mL = 10 mg/mL. For 1 mg: 1 / 10 = 0.1 mL = 10 units.

Community protocols describe swirling gently without shaking. Reconstituted vials are typically refrigerated at 2–8°C and used within 28 days per standard peptide storage guidelines.

Affiliate disclosure: vendor links in this article are affiliate links — The Peptide Catalog may earn a commission if you buy through them, at no additional cost to you.

Where These Numbers Come From

Selank is relatively unique — it has genuine human clinical trial data and regulatory approval in Russia.

Generalized Anxiety Disorder: Selank was compared to the benzodiazepine medazepam in GAD patients and showed comparable anxiolytic effects with additional antiasthenic and psychostimulant properties (Zozulya et al., 2008).

Enkephalinase inhibition: Selank potently inhibits enkephalin-degrading enzymes, increasing endogenous enkephalin levels and modulating the opioid system (Kost et al., 2001).

GABAergic modulation: Affects expression of genes involved in GABA neurotransmission, providing benzodiazepine-like effects through a different mechanism (Kasian et al., 2016).

BDNF regulation: Intranasal Selank regulates BDNF expression in the hippocampus, linking anxiolytic and neurotrophic effects (Inozemtseva et al., 2008).

Stacking Protocols

Documented protocols introduce each peptide separately to assess individual response. When multiple nasal sprays are combined, protocols describe spacing them 10-15 minutes apart.

Side Effects & Safety

• No sedation — unlike benzodiazepines, does not cause drowsiness or cognitive impairment
• No tolerance or dependence — confirmed in clinical evaluations
• Mild nasal irritation with intranasal use
• Occasional headache — typically first 1-2 days
• Mild fatigue or lightheadedness at higher doses (uncommon)
• Injection site irritation — minor, SC route
• Documented safety notes: Pregnancy/breastfeeding (no safety data), active infections (immunomodulatory effects — these groups were excluded from documented trials)

mg to Units Conversion

On a standard 100-unit insulin syringe, each "unit" equals 0.01 mL (so 100 units = 1 mL). Once Selank is reconstituted, the conversion from a target dose to syringe units depends on the chosen dilution.

The two reconstitution ratios most often described in community protocols are below.

Reconstitution A: 30 mg vial + 3 mL BAC water (10 mg/mL) — the standard dilution from the Quick Reference above.

Reconstitution B: 30 mg vial + 5 mL BAC water (6 mg/mL) — more BAC water for larger, easier-to-measure draws.

These conversions reflect the dilutions documented in community reconstitution protocols. They report how the math is described, not a recommended dosing schedule.